Long-Term Prophylaxis Cost-Effective for Von Willebrand Disease
Researchers sought to determine whether long-term prophylaxis against bleeds in patients with von Willebrand disease would be cost effective.
Von Willebrand Disease
Plasma-Derived VWF Effective for Young Children With Severe Von Willebrand Disease
Researchers sought to determine whether plasma-derived VWF would be effective in treating hemorrhage in young children with severe VWD.
Vonvendi Approved for Severe Type 3 von Willebrand Disease
Results showed the median ABR for all bleeds was reduced by 54.7%.
Ibrutinib May Reduce Risk of Bleeding Events in Acquired von Willebrand Syndrome Secondary to Waldenström Macroglobulinemia
Researchers described a case study that suggested ibrutinib may have beneficial effects in patients with acquired von Willebrand syndrome that is secondary to Waldenström macroglobulinemia.
Comparison of Approaches for Detection of Type 1 von Willebrand Disease
Researchers sought to determine whether the HemosIL VWF activity assay would be an effective method for identifying VWD.
VWF Associated With Thrombotic Complications in Patients With COVID-19
Researchers sought to determine whether von Willebrand factor may be a potential target for therapies to address thrombotic complications in patients with COVID-19.
Bleeding Patterns of Infants and Toddlers With von Willebrand Disease
Researchers sought to define bleeding patterns and other characteristics in infants and toddlers with von Willebrand disease.
Recombinant von Willebrand Factor Prophylaxis Effective at Preventing Bleeding in Patients With von Willebrand Disease
Researchers sought to determine whether recombinant VWF would be effective in reducing spontaneous bleeding for patients with severe VWD previously treated in an on-demand manner.
Updates on the Etiology, Diagnosis, Management of von Willebrand Syndrome and Hemophilia A
Acquired hemophilia A (AHA) and acquired von Willebrand syndrome (aVWS) are rare, life-threatening bleeding disorders that occur in patients with no bleeding history and no family history of a bleeding disorder.
First-in-Human Results Show Promise With BT200, a New Anti-von Willebrand Factor Agent
Researchers sought to determine whether BT200, a new anti-von Willebrand factor, would have efficacy in patients with von Willebrand disease.
- Loading...
Loading...
Next post in Bleeding Disorders
Loading... 
Loading...